Sponsored Content | Case Study | Contrast Media Injectors | October 30, 2019

Windsong Radiology Group Acquires MEDRAD Stellant FLEX using TechCARE CT Non-Obsolescence Program

Injection System Upgrade Drives Cost Efficiencies and Standardization Making Cost Savings Count

Windsong Radiology Group

Windsong Radiology Group

Bryan An

Bryan An

The MEDRAD Stellant FLEX offers the latest CT injection technology from Bayer.

The MEDRAD Stellant FLEX offers the latest CT injection technology from Bayer.

Windsong Radiology Group is a New York-based radiology practice with five locations. Recently, Windsong participated in a controlled commercial release (CCR) of the MEDRAD Stellant FLEX Injection System, the newest MEDRAD CT Injection System. Their participation allowed them to examine how the technology could improve their existing processes while lending their input to Bayer ahead of the company’s widespread platform release. Following the CCR, Windsong detailed how the MEDRAD Stellant FLEX Injection System and Bayer’s TechCARE non-obsolescence program have been key to helping them minimize operational costs, standardize care and avoid downtime.

Partnering with Bayer for their equipment and service needs allowed Windsong to achieve a number of primary metrics that are critical to their cost efficiency goals:

•    Staying current with equipment at an affordable cost

•    Maintaining reproducible and consistent image quality

•    Reducing operating costs

•    Benefitting from continued product reliability and maximizing up-time

Avoiding Obsolescence and Minimizing Downtime

Healthcare is evolving, and Windsong, like other radiology centers across the country, is faced with the balancing act of providing high-quality, value-based care while also meeting their budgetary needs.

“Our biggest hurdle right now is declining reimbursements,” said Bryan An, Windsong’s supervisor of MRI and CT. “The cost of doing business has not gone down, but our reimbursements have.”

Participating in the MEDRAD Stellant FLEX Injection System CCR gave Windsong the ability to experience how the new CT injection system is optimized to help imaging providers save on operational costs and limit downtime when supported by Bayer service. When coupled with the TechCARE non-obsolescence program — which delivers all the benefits of Bayer’s Radiology Equipment Service — MEDRAD Stellant FLEX Injection System provided Windsong with the boost they needed to maximize their profits in the face of declining reimbursements. It also helped them affordably enact a future-proofed plan for staying up to date with the most current injection system technology.

“One reason why we jumped on TechCARE is because, for a very small sum, we were able to replace all of our injectors. We spent a fraction of what it would normally cost,” said An. “Bayer realizes where medical imaging is headed,” added An, reinforcing that Windsong’s partnership with Bayer allowed the practice to avoid obsolescence as they continue to grow and consider opening additional office locations.

Capitalizing on Reliability

Windsong chose to participate in the CCR for MEDRAD Stellant FLEX due to their long-standing relationship with Bayer and the history of reliability with their MEDRAD injection systems. Sharing his personal experience, An credited MEDRAD reliability as a major reason that Windsong has been able to efficiently manage operational costs.

“I’ve been using MEDRAD injectors since 1998, and I can’t remember a time where we had any extended downtime because of an injector.” He added that when the practice was previously provided with a competitor’s injector at no cost, Windsong chose to return it due to inconsistent performance.

Windsong’s CCR experience was a positive one, said An. “If asked by another provider, I would recommend the MEDRAD Stellant FLEX because it’s a good product with high reliability, combined with great services provided by Bayer.”

Overcoming Financial Hurdles

Cost has always been a major factor in healthcare, but the current landscape is making it more difficult than ever for providers to maintain cost efficiency. It’s a challenge that Windsong knows well and has worked hard to effectively manage.

“We’ve experienced increased procedure volume in several modalities, yet our reimbursement has gone down significantly,” said An. “It’s an issue that’s all too familiar for radiology providers, and one that I believe Bayer is actively working on through their innovative portfolio offerings that can help customers control costs.”

Meeting Needs in the Current Climate

MEDRAD Stellant FLEX Injection System is designed to set providers up for success — both in terms of the radiology services they provide and their operational metrics. At Windsong, unique features like smaller syringes and improved loading have improved the practice’s workflow, as well as their ability to keep costs down over time. “The enhanced design of the MEDRAD Stellant FLEX Injection System made the decision to upgrade easy,” said An, noting the importance of reproducibility and that the injection system allows them to consistently inject contrast.

Windsong is far from alone in their need to choose equipment and services that align with their financial goals and challenges. An said that after working with the MEDRAD Stellant FLEX Injection System firsthand he would recommend that other radiology practices make the switch.

“You should treat your patients like your own family, and I would want my family to have a study done with a MEDRAD Injection System versus any other injector,” said An. He noted that as Windsong continues to expand their services, they plan to rely on Bayer’s comprehensive portfolio to ensure they provide the best possible care at the most reasonable cost.

Take Your Practice to the Next Level

Contact your rep or visit StellantFLEX.com today to learn more about the MEDRAD Stellant FLEX CT Injection System and to find out how Bayer’s proactive approach to supporting your non-obsolescence can benefit your radiology practice’s bottom line.

For more information: www.stellantflex.com

PP-M-STE-F-US-0099-1 October 2019 Bayer, the Bayer Cross, MEDRAD Stellant FLEX, MEDRAD, Stellant FLEX, and TechCARE are trademarks owned by and/or registered to Bayer in the U.S. and/or other countries.

Related Content

This novel agent, based on the essential nutrient manganese, has strong potential as a safer alternative to currently used contrast agents
News | Contrast Media | December 28, 2020
December 28, 2020 — Adding a contrast-enhancing agent to...
Bayer Radiology is announcing Radimetrics v3.0, the newest evolution of its enterprise dose management application.
News | Radiation Dose Management | December 11, 2020
December 11, 2020 — Bayer Radiology is announcing Radimetrics v3.0, the newest evolution of its enterprise dose manag
Bracco Diagnostics Inc. announced it will be showcasing its full portfolio of diagnostic imaging solutions in an immersive digital experience at the first all-virtual Radiological Society of North America (RSNA) annual meeting being held November 29 through December 5.
News | Contrast Media Injectors | November 17, 2020
November 17, 2020 — Bracco Diagnostics Inc.
Guerbet announced that it will highlight UNIK, a tailored solution for diagnostic imaging, at the 2020 annual meeting of the Radiological Society of North America (RSNA).
News | Contrast Media | November 17, 2020
November 17, 2020 — Guerbet announced that it will highlight UNIK, a tailored solution for diagnostic imaging, at the
This study found cardiac MRI gadolinium-based contrast agents are safe for patient use. Overall, there were only 556 acute adverse effects in 145,855 contrast-enhanced MRIs, with only 47 being classified as severe. 

This study found cardiac MRI gadolinium-based contrast agents are safe for patient use. Overall, there were only 556 acute adverse effects in 145,855 contrast-enhanced MRIs, with only 47 being classified as severe. 

Feature | Magnetic Resonance Imaging (MRI) | October 29, 2020
October 29, 2020 — Contrast agents used to improve views of the heart on magnetic resonance imaging (MRI) carry a ver
Vinai Gondi, M.D., the Director of Research at the Northwestern Medicine Chicago Proton Center, Co-director of the Brain Tumor Center at Northwestern Medicine Cancer Center, Warrenville, and lead author of the NRG-BN001 abstract.

Vinai Gondi, M.D., director of research at the Northwestern Medicine Chicago Proton Center, co-director of the Brain Tumor Center at Northwestern Medicine Cancer Center, Warrenville, and lead author of the NRG-BN001 abstract.

News | Intensity Modulated Radiation Therapy (IMRT) | October 27, 2020
October 27, 2020 — A...
Chest X-ray from a patient included in the study. Posteroanterior view, of a 79-year-old man with history of a previous pacemaker, with abandoned right atrial and right ventricular pacing leads on the right side at time of new cardiac resynchronization therapy defibrillator implant on the left side. Arrows indicate a nodular opacity in the right midlung concerning for mass. Find more images of patients in this study in Radiology: Cardiothoracic Imaging.

Chest X-ray from a patient included in the study. Posteroanterior view, of a 79-year-old man with history of a previous pacemaker, with abandoned right atrial and right ventricular pacing leads on the right side at time of new cardiac resynchronization therapy defibrillator implant on the left side. Arrows indicate a nodular opacity in the right midlung concerning for mass. Find more images of patients in this study in Radiology: Cardiothoracic Imaging.

Feature | Magnetic Resonance Imaging (MRI) | October 27, 2020
October 27, 2020 – Magn...
the Contrast Media Injectors Market is estimated to be USD 1.3 billion in 2020 and  projected to reach $1.9B by 2025, at a CAGR of 7.4% between 2020 and 2025

Getty Images

News | Contrast Media Injectors | September 02, 2020
September 2, 2020 — According to the new market research report "...